Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MERCK & CO., INC.

(MRK)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies
Analyst Recommendations on MERCK & CO., INC.
2021Daiwa Securities Starts Merck & Co. at Neutral With $70 Price Target
MT
2021ANALYST RECOMMENDATIONS : AT&T, BioNTech, Columbia Sports, Jefferies, Under Armour...
2021UBS Downgrades Merck & Co. to Neutral from Buy, Adjusts Price Target to $76 from $98
MT
2021Wells Fargo Starts Merck at Overweight With $90 Price Target
MT
2021Guggenheim Downgrades Merck to Neutral From Buy
MT
2021ANALYST RECOMMENDATIONS : Best Buy, Beyond Meat, Booking, Merck, Pfizer...
2021SVB Leerink Adjusts Merck & Co.'s Price Target to $102 from $105, Keeps Outperform Rati..
MT
2021Morgan Stanley Adjusts Merck & Co.'s Price Target to $82 from $88, Keeps Equalweight Ra..
MT
2021ANALYST RECOMMENDATIONS : Asos, Burberry, Greif, Merck, Mirion Technologies....
2021Citigroup Cuts Merck & Co. to Neutral From Buy, Price Target to $85 From $105
MT
2021Truist Securities Adjusts Merck's Price Target to $95 From $92, Reiterates Buy Rating
MT
2021BMO Capital Starts Merck at Market Perform With $91 Price Target
MT
2021Barclays Adjusts Price Target on Merck & Company to $94 From $92, Maintains Overweight ..
MT
2021Argus Upgrades Merck & Co. to Buy from Hold, Sets $110 Price Target
MT
2021Barclays Adjusts Price Target for Merck & Company to $94 From $92, Maintains Overweight
MT
2021Morgan Stanley Lifts Price Target on Merck to $90 From $88, Citing 'Strong' Q3, Higher ..
MT
2021MERCK : Morgan Stanley Adjusts Price Target on Merck & Company to $88 From $85, Maintains ..
MT
2021MERCK : Barclays Adjusts Merck & Co.'s Price Target to $92 from $87, Keeps Overweight Rati..
MT
2021MERCK : Receives Price Target Boost to $92 From $86 From Berenberg Bank; Hold Rating Maint..
MT
2021ANALYST RECOMMENDATIONS : Chipotle Mexican Grill, Coherent, Merck, Microchip Technology, V..
2021MERCK : Atlantic Equities Adjusts Merck & Company PT to $100 From $92, Maintains Overweigh..
MT
2021MERCK : SVB Leerink Adjusts Price Target on Merck & Company to $104 From $101, Maintains O..
MT
2021MERCK : Berenberg Bank Adjusts Merck & Company PT to $86 From $88, Maintains Hold Rating
MT
2021MERCK : Morgan Stanley Downgrades Merck & Company to Equalweight from Overweight, Adjusts ..
MT
2021ANALYST RECOMMENDATIONS : Amgen, Banner, Merck, Oracle, Phoenix...
2021MERCK : Goldman Sachs Adjusts Price Target for Merck to $104 From $102, Maintains Buy Rati..
MT
2021MERCK : SVB Leerink Adjusts Price Target on Merck & Company to $101 From $99, Maintains Ou..
MT
2021ANALYST RECOMMENDATIONS : Flutter, Hasbro, MGM Resort, Microsoft Vodafone...
2021MERCK : Truist Assumes Merck & Company at Buy Rating With $92 Price Target
MT
2021MERCK : RBC Lifts Price Target on Merck to $80 From $75 Ahead of Q2 Results, Reiterates Se..
MT
2021MERCK : JPMorgan Adjusts Merck's Price Target to $100 From $105, Maintains Overweight Rati..
MT
2021MERCK : Price Target From RBC Cut to $75 From $77 to Reflect Organon Spinoff, Sector Perfo..
MT
2021MERCK : Truist Securities Adjusts Merck's Price Target to $93 From $96, Maintains Buy Rati..
MT
2021MERCK : SVB Leerink Adjusts Merck & Co.'s Price Target to $99 from $102, Keeps Outperform ..
MT
2021MERCK : Argus Research Downgrades Merck & Company to Hold Rating From Buy
MT
2021MERCK : RBC Capital Adjusts Merck & Company PT to $77 From $79, Maintains Sector Perform R..
MT
2020MERCK : Bernstein Reinstates Merck & Co. at Outperform with $95 Price Target
MT
2020MERCK : Expects Nearly $2 Billion Covid-19 Revenue Impact in 2020
DJ
2020Pharma Companies Split on Coronavirus Vaccine Pricing Plans
DJ
2020MERCK & CO INC : RBC gives a Neutral rating
MD
2019Bristol-Myers posts better-than-expected results, Opdivo growth slows
RE
2019MERCK & CO INC : Goldman Sachs remains Neutral
MD
2019MERCK & CO INC : JP Morgan remains Neutral
MD
2019AstraZeneca Imfinzi combination fails advanced lung cancer study
RE
2019Elanco to become No.2 in animal health with $7.6 billion Bayer deal
RE
2019Elanco to become No.2 in animal health with $7.6 billion Bayer deal
RE
2019Eliquis, Orencia sales propel Bristol-Myers to strong second quarter
RE
2019Merck KGaA clinches $6.5 billion Versum takeover in bet on electrochemicals
RE
2019Merck KGaA clinches $6.5 billion Versum takeover in bet on electrochemicals
RE
2019Biogen scraps two Alzheimer drug trials, wipes $18 billion from market value
RE
2018Pfizer to replace longtime CEO Read with veteran Bourla
RE
2018Pfizer to replace longtime CEO Read with veteran Bourla
RE
2018Roche steps up efficiency drive to take sting out of biosimilars
RE
2018Roundup cancer verdict sends Bayer shares sliding
RE
2018Roundup cancer verdict sends Bayer shares sliding
RE
2018Clamour for GSK shingles shot points to bigger profits
RE
2018AstraZeneca cancer drug hits second goal by extending survival
RE
2018Keytruda sales power Merck to quarterly beat
RE
2018Keytruda sales power Merck to quarterly beat
RE
2018GlaxoSmithKline prescribes commercial reboot for pharma division
RE
2018GlaxoSmithKline prescribes commercial reboot for pharma division
RE
2018Bristol-Myers to pay $1.85 billion in cancer deal with Nektar
RE
2018U.S. tax change to help Roche's 2018 profit growth outpace sales
RE
2017Roche drug cocktail doubles chance of holding lung cancer at bay
RE
2017GSK wins U.S. shingles vaccine approval, UK nod for gene therapy
RE
2017AstraZeneca shares surge after key drug shows promise in lung cancer trial
RE
2017MERCK : 2017 forecast reassuring; full-speed ahead with Keytruda
RE
2017Bristol-Myers lung cancer delay slams shares, keeps Merck in lead
RE
2017Bristol-Myers shares fall on lung cancer timeline setback
RE
2016Pharma, biotech shares soar as Trump win calms pricing talk
RE
2016Pharma, biotech shares soar as Trump win calms pricing talk
RE
2016Drugmakers under fire for possible U.S. price fixing
RE
2016Bristol lung-cancer setback puts rival Merck drug in driver seat
RE
2016MERCK : China's drugs watchdog struggles as senior staff lured away by industry
RE
2016BRISTOL MYERS SQUIBB : Merck sales disappoint as Januvia, Remicade fall short
RE
1  2Next
Upcoming event on MERCK & CO., INC.